1 Year Total Returns (Daily) Chart

View 1 Year Total Returns (Daily) for COCP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View 1 Year Total Returns (Daily) Chart
Start Trial

Historical 1 Year Total Returns (Daily) Data

View and export this data back to 2010. Start Trial.
Date Value
September 14, 2026 -25.95%
September 11, 2026 -13.89%
September 10, 2026 -15.75%
September 09, 2026 -14.48%
September 08, 2026 -21.33%
September 04, 2026 -22.65%
September 03, 2026 -22.62%
September 02, 2026 -22.67%
September 01, 2026 -25.33%
August 31, 2026 -22.67%
August 28, 2026 -29.94%
August 27, 2026 -26.45%
August 26, 2026 -27.51%
August 25, 2026 -26.62%
August 24, 2026 -29.14%
August 21, 2026 -23.68%
August 20, 2026 -23.03%
August 19, 2026 -25.16%
August 18, 2026 -30.77%
August 17, 2026 -35.69%
August 14, 2026 -33.33%
August 13, 2026 -34.52%
August 12, 2026 -32.12%
August 11, 2026 -32.50%
August 10, 2026 -33.33%
Date Value
August 07, 2026 -35.76%
August 06, 2026 -38.32%
August 05, 2026 -38.18%
August 04, 2026 -49.47%
August 03, 2026 -49.19%
July 31, 2026 -52.60%
July 30, 2026 -48.04%
July 29, 2026 -49.96%
July 28, 2026 -45.94%
July 27, 2026 -42.58%
July 24, 2026 -44.44%
July 23, 2026 -43.90%
July 22, 2026 -41.49%
July 21, 2026 -42.23%
July 20, 2026 -43.29%
July 17, 2026 -43.79%
July 16, 2026 -43.11%
July 15, 2026 -43.66%
July 14, 2026 -46.57%
July 13, 2026 -46.67%
July 10, 2026 -35.67%
July 09, 2026 -35.26%
July 08, 2026 -35.39%
July 07, 2026 -32.45%
July 06, 2026 -31.58%

Total Return Definition

The Total return is the change in price over a specific period of time that includes dividends and distributions paid.

Read full definition.

1 Year Total Returns (Daily) Range, Past 5 Years

View 1 Year Total Returns (Daily) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

1 Year Total Returns (Daily) Benchmarks

View 1 Year Total Returns (Daily) Benchmarks
Start Trial
CNBX Pharmaceuticals, Inc. -66.67%
GB Sciences, Inc. 0.00%
Arvinas, Inc. 8.53%
Fulcrum Therapeutics, Inc. -45.86%
Definium Therapeutics, Inc. 326.4%